Tivic Health Systems (TIVC)
NASDAQ:TIVC
Top Page
Tivic Health Systems
(NASDAQ:TIVC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.98
▼(-28.99% Downside)
Action:ReiteratedDate:03/31/26
The score is constrained primarily by weak financial performance (shrinking revenue base, large operating losses, cash burn, and balance-sheet erosion) and a bearish technical setup with the stock below major moving averages. The earnings call provides partial offset due to progress on the biopharma pivot and some liquidity improvement, but losses, delays, and an unhelpful negative P/E keep the overall risk high.
Positive Factors
Strategic pivot to biopharma (Entolimod)
Shifting from consumer devices to an immunotherapy focus around Entolimod creates a durable, higher‑value addressable market and opens access to U.S. government countermeasure funding. IND transfers and cell line verification materially de‑risk near‑term development steps and improve prospects for non‑dilutive contracts and stockpile procurements.
Negative Factors
Multi‑year revenue contraction
Sustained decline in product revenue signals weak commercial traction and limited scale economics. Persistent top‑line erosion undermines the company’s ability to self‑fund R&D and manufacturing, increases reliance on external capital, and raises execution risk as it transitions to a development‑stage biopharma model.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic pivot to biopharma (Entolimod)
Shifting from consumer devices to an immunotherapy focus around Entolimod creates a durable, higher‑value addressable market and opens access to U.S. government countermeasure funding. IND transfers and cell line verification materially de‑risk near‑term development steps and improve prospects for non‑dilutive contracts and stockpile procurements.
Read all positive factors
Tivic Health Systems (TIVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.91M
Dividend YieldN/A
Average Volume (3M)99.84K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-49.63%
EPS Growth82.22%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,877,926
10 Day Avg. Volume91,463
30 Day Avg. Volume99,839
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)1.09
P/FCF Ratio-1.10
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue2.84
Enterprise Value/Gross Profit33.84
Enterprise Value/Ebitda-1.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tivic Health Systems Business Overview & Revenue Model
Company Description
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus an...
How the Company Makes Money
Tivic Health Systems primarily makes money by selling its ClearUP device and related accessories to customers, with revenue recognized from product sales through direct-to-consumer channels and/or retail or distribution partners. To the extent the...
Tivic Health Systems Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Neutral
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.Positive Updates
Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Negative Updates
Increased Net Loss
Net loss for Q3 2025 was $2.6 million compared to $1.4 million in Q3 2024.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Read all positive updates
Company Guidance
During the third quarter of 2025, Tivic Health Systems reported significant progress in its strategic transformation towards the biopharmaceutical market, having licensed entolimod and related assets to pivot from bioelectronics to biologic pharmaceuticals. The company is focusing on entolimod as a military countermeasure for acute radiation syndrome (ARS) and has moved forward with transferring two INDs related to ARS and advanced cancer. Financially, Tivic saw revenue net of returns at $140,000 for the quarter, an increase from $126,000 in the previous year, although nine-month revenue decreased to $302,000 from $600,000 due to reduced advertising spend. The cost of sales rose to $291,000, influenced by a $230,000 inventory reserve, while gross margins excluding this reserve improved to 42% from 35%. Operating expenses increased to $2,300,000 from $1,500,000 due to heightened R&D investments and corporate costs. The net loss widened to $2,600,000 from $1,400,000, and cash reserves grew to $3,500,000, supported by additional financing tranches totaling $3,800,000 during the quarter.Tivic Health Systems Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
25
Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 382.00K | 780.00K | 1.18M | 1.84M | 1.17M |
| Gross Profit | 32.00K | 2.00K | 287.00K | 299.00K | -129.00K |
| EBITDA | -768.00K | -5.31M | -8.06M | -9.92M | -6.65M |
| Net Income | 0.00 | -5.66M | -8.24M | -10.10M | -8.49M |
Balance Sheet | |||||
| Total Assets | 15.00K | 2.81M | 5.16M | 6.02M | 15.04M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 2.00M | 3.40M | 3.52M | 12.97M |
| Total Debt | 0.00 | 0.00 | 369.00K | 530.00K | 708.00K |
| Total Liabilities | 0.00 | 272.00K | 1.58M | 2.39M | 1.76M |
| Stockholders Equity | 0.00 | 2.54M | 3.58M | 3.63M | 13.27M |
Cash Flow | |||||
| Free Cash Flow | -380.00K | -5.72M | -8.63M | -8.93M | -5.61M |
| Operating Cash Flow | -380.00K | -5.72M | -8.51M | -8.92M | -5.61M |
| Investing Cash Flow | 0.00 | 0.00 | -118.00K | -11.00K | 0.00 |
| Financing Cash Flow | 0.00 | 4.33M | 8.51M | -528.00K | 17.54M |
Tivic Health Systems Technical Analysis
Neutral
1.38
Price Trends
0.95
Positive
1.36
Negative
2.34
Negative
Market Momentum
<0.01
Negative
54.17
Neutral
23.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIVC, the sentiment is Neutral. The current price of 1.38 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.95, and below the 200-day MA of 2.34, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.17 is Neutral, neither overbought nor oversold. The STOCH value of 23.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TIVC.
Tivic Health Systems Risk Analysis
Tivic Health Systems disclosed 48 risk factors in its most recent earnings report. Tivic Health Systems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tivic Health Systems Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $14.26M | ― | -647.90% | ― | -44.57% | 55.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $2.83M | -0.28 | -191.39% | ― | ― | 76.53% | |
44 Neutral | $2.91M | ― | -202.20% | ― | -49.63% | 82.22% | |
42 Neutral | $1.84M | -0.18 | -145.52% | ― | ― | 97.70% | |
41 Neutral | $2.52M | -0.69 | -6046.59% | ― | -8.93% | 97.80% |
* Healthcare Sector Average
TIVC
Tivic Health Systems
1.01
-3.86
-79.26%
NUWE
Nuwellis
1.09
-39.23
-97.30%
AEMD
Aethlon Medical
2.15
-25.79
-92.30%
BBLG
Bone Biologics
1.16
-4.00
-77.52%
MOVE
Movano
11.80
-1.60
-11.94%
BJDX
Bluejay Diagnostics
1.89
-11.11
-85.46%
Tivic Health Systems Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Tivic Health Unveils 2025 Results and Strategic Pivot
Positive
Mar 25, 2026
On March 25, 2026, Tivic Health Systems reported its 2025 financial and operational results, marking completion of a major strategic pivot from consumer neuromodulation into a focused immunotherapy business built around its Entolimod platform and ...
Delistings and Listing ChangesRegulatory Filings and Compliance
Tivic Health Systems Receives Nasdaq Minimum Bid Price Notice
Negative
Mar 20, 2026
On March 19, 2026, Tivic Health Systems, Inc. disclosed that it had received a notice from Nasdaq indicating its shares had traded below the $1.00 minimum bid price for at least 30 consecutive business days, putting the company out of compliance w...
Business Operations and Strategy
Tivic Health Consolidates Headquarters at New San Antonio Campus
Positive
Mar 13, 2026
On March 13, 2026, Velocity Bioworks entered into an eight-year lease for an approximately 8,024-square-foot microbial facility in San Antonio, with a one-time five-year extension option and an exclusive right to buy the building and property with...
Business Operations and StrategyShareholder Meetings
Tivic Health Cancels Shareholder Meeting and Withdraws Proposals
Negative
Mar 12, 2026
On February 19, 2026, Tivic Health Systems convened but immediately adjourned a special shareholder meeting after less than one-third of eligible shares were represented, leaving the company without the quorum required under its bylaws to proceed ...
Business Operations and StrategyExecutive/Board Changes
Tivic Health Appoints New CEO to Drive Biopharma Pivot
Positive
Mar 4, 2026
On March 4, 2026, Tivic Health Systems announced that biotech veteran Michael K. Handley had been appointed chief executive officer and director, succeeding founding CEO Jennifer Ernst, who will continue to support the company during the transitio...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Tivic Health Establishes Flexible $50 Million Equity Line
Neutral
Feb 9, 2026
On February 6, 2026, Tivic Health Systems, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital, giving Tivic the right, but not the obligation, to sell up to $50 million of newly issued common shares, subject to an exchang...
Business Operations and Strategy
Tivic Health Highlights TLR5 Pipeline in New Investor Presentation
Positive
Jan 20, 2026
On January 20, 2026, Tivic Health Systems, Inc. announced it had made an investor presentation available on its website, outlining a clinical pipeline centered on its TLR5 agonist portfolio, led by Entolimod in late Phase III development for acute...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.